Bulletin from Artimplant AB's Annual Meeting of Stockholders 2011

Bulletin from Artimplant AB's Annual Meeting of Stockholders 2011

Adoption of financial statements, disposition of result and discharge of
directors and officers
The financial statements of 2010 for the group and the parent company
were adopted. The Annual Meeting decided to set off the parent company's
retained loss of SEK 5,462,093 against the statutory reserve. The
directors and officers of the Company were granted discharge.

Election of Board members and auditor
Anders Cedronius was elected as chairman of the Board and Håkan
Johansson was reelected as ordinary Board member. John Arnold, Rickard
Brånemark and Lars Peterson were elected as new ordinary Board members.
Ernst & Young AB, with Björn Grundvall as responsible auditor, was
elected for a four year period at the AGM 2010 and remains until AGM
2014.

Adoption of fees
The Annual Meeting decided that the fee to the Board of Directors shall
be adjusted to SEK 240,000 (280,000) to the chairman and SEK 120,000
(140,000) to ordinary Board members. It was also decided that the fee to
the chairman of the audit committee shall be SEK 20,000 (40,000) and the
fee to the other members shall be SEK 10,000 (20,000). It was decided
that no remuneration committee is necessary. The audit fee will the
upcoming year be in accordance with the existing agreement for audit
services, SEK 200,000 per year.

Election committee
The Annual Meeting decided that the election committee before the Annual
Meeting of 2011, planned to May 2012, shall be appointed by
representatives from the three largest stockholders, according to voting
power, as of September 30, 2011.

Principles for remuneration to senior management
The Annual Meeting adopted the principles for remuneration to senior
management as suggested by the Board of Directors.

All above decisions were taken unanimously.

The presentation made by the CEO at the Annual Meeting is available at
the Company's web page:
http://www.artimplant.com/investors-media/presentations.html (http://www
.artimplant.com/investors-media/presentations.html)

For additional information, please contact:
Anders Cedronius, Chairman, phone +46 (0)706-42 27 45

Kjell Thörnbring, Interim CEO, phone +46 (0)31-746 56 54, +46 (0)703 11
90 25,
kjell.thornbring@artimplant.com (kjell.thornbring@artimplant.com)

Further information is available at www.artimplant.com. To subscribe to
future press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html (htt
p://www.artimplant.com/investors-media/subscribe-to-press-releases.html)

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body
functions and improve quality of life. Our products, made from Artelon®,
meet unmet clinical needs and are marketed in a growing number of
therapy areas. Artimplant produces implants for treatment of
osteoarthritis in hands and feet, for shoulder and other soft tissue
injuries as well as oral surgery and veterinary medical applications.

Artimplant is a public company listed on the NASDAQ OMX Stockholm
Exchange in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the
U.S. Private Securities Litigation Reform Act of 1995. Readers are
cautioned not to place undue reliance on these forward-looking
statements. Actual results may differ materially from those indicated by
these forward-looking statements as a result of risks and uncertainties
impacting the Company's business including increased competition; the
ability of the Company to expand its operations and to attract and
retain qualified professionals; technological obsolescence; general
economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the
Swedish Financial Instruments Act and the Swedish Securities Exchange
and Clearing Operations Act and/or stock market agreements. Information
was made available for publication on May 5, 2011 at 8:45 AM (CET).